Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
The present invention relates to methods of treating a subject with a lysosomal disorder, by administering an agent for enzyme replacement therapy and an agent for anti-TNF-α therapy; by administering a pentosan polysulfate therapy; or by administering a substrate reduction therapy and an anti-TNF-α therapy. The invention further relates to a method of reducing inflammatory cytokines in a subject with a lysosomal disorder that is being treated by enzyme replacement therapy, by administering an agent for anti-TNF-α therapy.
1. A method of treating a subject with a lysosomal storage disorder, said method comprising:
selecting a subject with a lysosomal storage disorder and
administering to the selected subject an agent for an enzyme replacement therapy, and an agent for an anti-TNF-α treatment under conditions effective to treat the lysosomal storage disorder in the selected subject.
2. The method of claim 1 , wherein the agent for anti-TNF-α therapy is pentosan polysulfate (PPS).
3. The method of claim 1 further comprising:
administering an additional therapy.
4. A method of reducing inflammatory cytokines in a subject with a lysosomal storage disorder that is being treated by an enzyme replacement therapy, said method comprising:
administering to the subject an agent for an anti-TNF-α treatment under conditions effective to reduce the inflammatory cytokines in the subject.
5. The method of claim 4 further comprising:
selecting a subject with a skeletal pathology associated with a lysosomal storage disorder to be subjected to said administering.
6. The method of claim 4 , wherein the agent for anti-TNF-α therapy is pentosan polysulfate (PPS).
7. A method of treating a subject with a lysosomal storage disorder, said method comprising:
selecting a subject with a lysosomal storage disorder and
administering pentosan polysulfate (PPS) to the selected subject under conditions effective to treat the lysosomal storage disorder in the selected subject.
8. The method of claim 7 further comprising:
administering an additional therapy.
9. The method of claim 8 , wherein the additional therapy is selected from the group consisting of bone marrow transplant, chaperone therapy, and gene therapy.
10. The method of claim 7 , wherein the lysosomal storage disorder is selected from the group consisting of sphingolipidoses, mucopolysaccharide storage disease (mucopolysaccharidoses), glycoproteinoses, mucolipidoses, glycogenosis type II, ceroid lipofuscinoses, and other abnormalities of lysosomal protein function.
11. The method of claim 7 , wherein the lysosomal storage disorder is a sphingolipidosis, said sphingolipidosis being Niemann-Pick disease.
12. The method of claim 7 , wherein the lysosomal storage disorder is a mucopolysaccharidosis, said mucopolysaccharidosis being MPS I (Hurler/Schie Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), MPS III (Sanfilippo Syndrome), MPS IV (Morquio Syndrome), or MPS VII (Sly Disease).
13. The method of claim 7 , wherein said administering is carried out orally, by inhalation, by intranasal instillation, topically, transdermally, parenterally, subcutaneously, by intravenous injection, by intra-arterial injection, by intramuscular injection, intraplurally, intraperitoneally, or by application to mucous membrane.
14. The method of claim 7 further comprising:
repeating said administering.
15. The method of claim 7 , wherein the subject is an infant or juvenile.
16. The method of claim 7 , wherein the subject is an adult.
17. The method of claim 7 , wherein the subject has a skeletal pathology associated with a lysosomal storage disorder.
18. A method of treating a subject with a skeletal pathology associated with a lysosomal storage disorder, said method comprising:
selecting a subject with a skeletal pathology associated with a lysosomal storage disorder and
administering to the selected subject an agent for substrate reduction therapy and an agent for an anti-TNF-α treatment under conditions effective to treat the skeletal pathology associated with lysosomal storage disorder in the subject.
19. The method of claim 18 , wherein the agent anti-TNF-α therapy is pentosan polysulfate (PPS).
20. The method of claim 18 further comprising:
administering an additional therapy.